Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.

@article{vanLeeuwen1994LeukemiaRF,
  title={Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.},
  author={Flora E. van Leeuwen and Astrid M J Chorus and Alexandra W van den Belt-Dusebout and Anton Hagenbeek and R. Noyon and E H van Kerkhoff and Herbert Michael Pinedo and Reinier Somers},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1994},
  volume={12 5},
  pages={
          1063-73
        }
}
PURPOSE The development of leukemia is one of the most serious long-term complications of modern treatment for Hodgkin's disease (HD). This study was undertaken to examine the relation between risk of leukemia and various treatment factors (including cumulative dose of cytostatic drugs and interaction with radiotherapy [RT]), while also assessing the effect of treatment-induced bone marrow damage. PATIENTS AND METHODS We conducted a case-control study in a cohort of 1,939 patients treated for… Expand
The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
TLDR
Case-control analysis indicated advanced stage, type and duration of CT and extension of RT as significant risk factors for leukemia, and combined modality therapy with MOPP and extensive RT (including abdomen and pelvis), and the use of lomustine added to the leukemogenic risk of MopP alone were indicated. Expand
Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
TLDR
The observed risk of SHM is smaller than in other studies (adults and children) in which chemotherapy with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) was given, and this difference can be attributed to the lower cumulative doses of alkylating agents, the absence of mechlorethyamine in the chemotherapy, and the small number of patients who needed salvage therapy in the presented cohort. Expand
Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies
TLDR
S-AML and s-MDS increasingly represent a problem in modern cancer therapy because of better treatment strategies, which result in improved cure rates, and are likely to be related to prior treatment rather than to high-dose chemotherapy itself. Expand
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
TLDR
BEACOPP escalated moderately increases the risk of secondary AML/MDS but not NHL, and no differences were found between other chemotherapies of advanced stages and intermediate stages. Expand
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
TLDR
Limiting the dose of AA and decreased need for secondary treatments have significantly reduced the incidence of t-AML/MDS, which was extremely rare in the G studies (Stanford V era). Expand
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.
TLDR
Past treatments with alkylating agents and radiation therapy for Hodgkin's disease were associated with an increased risk of lung cancer in a dose-dependent and additive fashion, but the precise risk estimates should be interpreted cautiously, given the possible residual and enhancing effects of tobacco. Expand
Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors.
TLDR
Patients treated for ESFT with intensive chemotherapy that includes large doses of alkylators, topoisomerase II inhibitors, and G-CSF characteristically have persistently elevated MCVs and decreased platelet counts after completion of therapy. Expand
Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
This study describes the magnitude of risk of therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) in 578 individuals diagnosed with Ewing sarcoma and enrolled on Children's OncologyExpand
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
TLDR
A meta-analysis based on individual patient data from patients treated for newly diagnosed Hodgkin lymphoma found that there was a decrease in the risk of secondary malignancy incidence after current treatment approaches comprising chemotherapy and/or radiotherapy, corresponding to an estimated reduction of eight-year SMN risk. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Risk of leukemia after chemotherapy and radiation treatment for breast cancer.
TLDR
Although leukemia occurs in few patients with breast cancer, significantly elevated risks were linked to treatments with regional radiation and alkylating agents, and melphalan is a more potent leukemogen than cyclophosphamide or radiotherapy. Expand
Leukemia following Hodgkin's disease.
TLDR
It is concluded that chemotherapy for Hodgkin's disease greatly increases the risk of leukemia and that this increased risk appears to be dose-related and unaffected by concomitant radiotherapy. Expand
RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE Relation to Age, Cumulative Dose of Alkylating Agents, and Time from Chemotherapy
TLDR
391 patients treated intensively for Hodgkin's disease were followed for up to 15 years to evaluate the risk of therapy-related acute non-lymphocytic leukaemia (t-ANLL) and preleukaemia and the general risk of solid tumours was not increased. Expand
Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease.
TLDR
There appears to be a period of increased risk in patients treated with chemotherapy and radiation, after which the risk of secondary leukemia decreases, and patients surviving for more than 11 years after treatment appear to be at no increased risk of acute leukemia. Expand
Subsequent development of acute non‐lymphocytic leukemia in patients treated for Hodgkin's disease
TLDR
The treatment characteristics associated with an increased risk of developing ANLL were extensive radiotherapy, splenectomy and the chemotherapy combination of vincristine, procarbazine and mechlorethamine. Expand
Leukemia Following Chemotherapy for Ovarian Cancer
TLDR
The drugs cyclophosphamide, chlorambucil, melphalan, thiotepa, and treosulfan were independently associated with significantly increased risks of leukemia, as was the combination of doxorubicin hydrochloride and cisplatin. Expand
Second cancers after radiotherapy and chemotherapy for early stages of Hodgkin's disease.
  • M. Henry-Amar
  • Medicine
  • Journal of the National Cancer Institute
  • 1983
TLDR
The first important risk factor for developing an SC was polychemotherapy, and the second was age over 40 years, which suggest that combination chemotherapy may be responsible for both acute leukemias and other SC. Expand
Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease.
TLDR
The results strongly suggest that extended high-dose irradiation and MOPP chemotherapy should not be combined for the treatment of HD. Expand
Second primary cancers following treatment of Hodgkin's disease.
TLDR
A cohort study designed to evaluate the carcinogenicity of treatment for Hodgkin's disease (HD) was conducted and an analysis of follow-up findings through 1978 is presented. Expand
Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation.
TLDR
The risk of secondary leukaemia was largely related to the overall quantity of treatment, although exposure to lomustine seemed to be an important risk factor. Expand
...
1
2
3
4
...